ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated...
News
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom...
ORYZON to Give Updates on Corporate Progress in May-June
BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023MADRID and...
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss...
Immutep to Participate in the JMP Securities Life Sciences Conference
Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform
NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and...
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety...
Humacyte Announces Publication in Lancet Regional Health – Europe Presenting Use of Human Acellular Vessel™ (HAV™) to Treat Vascular Injuries in Ukraine
First regenerative medicine technology used in battlefield trauma Ukrainian surgeons trained on HAV procedures over video conferencing DURHAM, N.C., May...
CymaBay Names Harish Shantharam Chief Financial Officer
Proven Leader in Building Financial Organizations to Prepare Company for Successful Commercialization Planning for Seladelpar Launch as it Completes Development...
TriLink BioTechnologies Introduces Latest mRNA Capping Technology: CleanCap® M6 analog
Newest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to...
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual...
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
IBSRELA provides meaningful reduction of multiple abdominal symptoms Patient-reported outcomes are strongly correlated with IBS-C abdominal symptom score WALTHAM, Mass.,...
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platformSEATTLE, May...
Arbutus to Present at JMP Securities Life Sciences Conference
WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
Initiated Phase 2 clinical trial for XTX202, a tumor-activated IL-2 Anticipate reporting preliminary Phase 1 safety, PK, PD, and anti-tumor...
Healthcare Triangle Reports First Quarter 2023 Results
PLEASANTON, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc (Nasdaq: HCTI) (“HCTI” or the "Company"), a leader in digital...
Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results
New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy...
Kura Oncology to Participate in JMP Securities Life Sciences Conference
SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
On track to provide clinical update from dose-escalation portion of Phase 1 clinical trial of EGFR MasterKey inhibitor BDTX-1535 in...